Technology Listings

Virus-like Particle (VLP) Vaccine for Respiratory Syncytial Virus (RSV) Infection


Safe and effective Respiratory Syncytial Virus (RSV) vaccine.

Key Benefits
  • VLPs are safer than live replicating vectored vaccines because of their lack of infectivity.
  • VLPs are highly immunogenic and can elicit both cellular and humoral responses.
Technical Summary

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness in infants and children worldwide. In the U.S., roughly 70,000 to 120,000 infants are hospitalized annually with RSV related pneumonia or bronchiolitis. Effective therapies are not widely available, and there is no licensed vaccine. Approaches to develop subunit vaccines, attenuated viruses, DNA or live vector vaccines have been used but have not resulted in a licensed vaccine. New approaches are therefore urgently needed to develop effective RSV vaccines.

Emory researchers have developed a novel RSV VLP vaccine. This VLP is highly immunogenic, eliciting both cellular and humoral responses. Vaccination with this RSV VLP provides effective protection against RSV infection. Animal studies have shown that administration of the vaccine elicits antibody response and significantly reduced lung viral replication.

Developmental Stage

Pre-clinical mouse studies have shown that immunization with RSV VLPs provide strong immune responses with effective protection against RSV infection.

Patent Information
Tech ID: 11175
Published: 9/15/2011

Hyeon (sean) Kim
Licensing Associate
Emory University

Fu shi Quan
Richard Compans
Martin Moore

Microbiology/Infectious Diseases